Please assess the completion status of the following clinical trial:

Trial Title: A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Medically stable men or women 18 to 69 years of age (inclusive)~* Work in any capacity (including physicians and midwives with admitting privileges), volunteer, or student at participating hospital~* Able to read, understand, and respond to questionnaires~* Able to read, understand, and sign an informed consent form~* Available for follow-up for 8 days post-vaccination~* Participants in Part B (repeat administration) of the study must also have participated in the previous randomized control trial of self- versus nurse-administered intradermal influenza vaccine and must have attempted to self-administer the vaccine~Exclusion Criteria:~* Already received 2012-13 influenza vaccine~* History of a severe reaction following influenza vaccination~* Known allergy to components of study vaccines (Intanza® or Vaxigrip®)~* History of Guillain-Barré Syndrome (GBS) within 8 weeks following influenza vaccination~* Acute febrile illness (\>37.9ºC orally) within the past 48 hours (participation may be deferred until recovery for these subjects)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: t

Study Arms:
- Nurse-administered IM (Type: EXPERIMENTAL): Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
- Self-administered intradermal (Type: EXPERIMENTAL): Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
- Repeat self-administration intradermal (Type: ACTIVE_COMPARATOR): Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study

Based on this trial design, predict the completion outcome and termination type (if applicable).